Kissei Pharmaceutical Co Ltd - Product Pipeline Review

Global Markets Direct’s, ‘Kissei Pharmaceutical Co Ltd - Product Pipeline Review - 2016’, provides an overview of the Kissei Pharmaceutical Co Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kissei Pharmaceutical Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Kissei Pharmaceutical Co Ltd

The report provides overview of Kissei Pharmaceutical Co Ltd including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Kissei Pharmaceutical Co Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Kissei Pharmaceutical Co Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Kissei Pharmaceutical Co Ltd’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kissei Pharmaceutical Co Ltd

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kissei Pharmaceutical Co Ltd’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Kissei Pharmaceutical ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Kissei Pharmaceutical Co Ltd Snapshot 7

Kissei Pharmaceutical Co Ltd Overview 7

Key Facts 7

Kissei Pharmaceutical Co Ltd - Research and Development Overview 8

Key Therapeutic Areas 8

Kissei Pharmaceutical Co Ltd - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products - Out-Licensed Products 15

Out-Licensed Products/Combination Treatment Modalities 16

Kissei Pharmaceutical Co Ltd - Pipeline Products Glance 17

Kissei Pharmaceutical Co Ltd - Late Stage Pipeline Products 17

Pre-Registration Products/Combination Treatment Modalities 17

Phase III Products/Combination Treatment Modalities 18

Kissei Pharmaceutical Co Ltd - Clinical Stage Pipeline Products 19

Phase II Products/Combination Treatment Modalities 19

Phase I Products/Combination Treatment Modalities 20

Kissei Pharmaceutical Co Ltd - Early Stage Pipeline Products 21

Preclinical Products/Combination Treatment Modalities 21

Kissei Pharmaceutical Co Ltd - Drug Profiles 22

AS-192426900 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

AS-192781900 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

AS-193280400 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

bedoradrine sulfate - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

KDT-3594 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

KLH-2109 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

KSI-6666 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

KTA-439 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

mitiglinide - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

ozagrel - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

remogliflozin etabonate - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

rovatirelin - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecule to Inhibit SGLT1 for Postprandial Hyperglycemia - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

YS-110 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Kissei Pharmaceutical Co Ltd - Pipeline Analysis 44

Kissei Pharmaceutical Co Ltd - Pipeline Products by Target 44

Kissei Pharmaceutical Co Ltd - Pipeline Products by Route of Administration 46

Kissei Pharmaceutical Co Ltd - Pipeline Products by Molecule Type 47

Kissei Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action 48

Kissei Pharmaceutical Co Ltd - Dormant Projects 50

Kissei Pharmaceutical Co Ltd - Discontinued Pipeline Products 51

Discontinued Pipeline Product Profiles 52

diquafosol tetrasodium 52

KEA-0477 52

KGA-3235 52

KLS-0611 52

KUX-1151 52

neflamapimod 52

remogliflozin etabonate 52

ritobegron 52

sergliflozin 53

Kissei Pharmaceutical Co Ltd - Company Statement 54

Kissei Pharmaceutical Co Ltd - Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Appendix 56

Methodology 56

Coverage 56

Secondary Research 56

Primary Research 56

Expert Panel Validation 56

Contact Us 56

Disclaimer 57

List of Tables

List of Tables

Kissei Pharmaceutical Co Ltd, Key Facts 7

Kissei Pharmaceutical Co Ltd - Pipeline by Indication, 2016 10

Kissei Pharmaceutical Co Ltd - ...

List of Tables

Kissei Pharmaceutical Co Ltd, Key Facts 7

Kissei Pharmaceutical Co Ltd - Pipeline by Indication, 2016 10

Kissei Pharmaceutical Co Ltd - Pipeline by Stage of Development, 2016 11

Kissei Pharmaceutical Co Ltd - Monotherapy Products in Pipeline, 2016 12

Kissei Pharmaceutical Co Ltd - Partnered Products in Pipeline, 2016 13

Kissei Pharmaceutical Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016 14

Kissei Pharmaceutical Co Ltd - Out-Licensed Products in Pipeline, 2016 15

Kissei Pharmaceutical Co Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016 16

Kissei Pharmaceutical Co Ltd - Pre-Registration, 2016 17

Kissei Pharmaceutical Co Ltd - Phase III, 2016 18

Kissei Pharmaceutical Co Ltd - Phase II, 2016 19

Kissei Pharmaceutical Co Ltd - Phase I, 2016 20

Kissei Pharmaceutical Co Ltd - Preclinical, 2016 21

Kissei Pharmaceutical Co Ltd - Pipeline by Target, 2016 45

Kissei Pharmaceutical Co Ltd - Pipeline by Route of Administration, 2016 46

Kissei Pharmaceutical Co Ltd - Pipeline by Molecule Type, 2016 47

Kissei Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action, 2016 49

Kissei Pharmaceutical Co Ltd - Dormant Developmental Projects,2016 50

Kissei Pharmaceutical Co Ltd - Discontinued Pipeline Products, 2016 51

Kissei Pharmaceutical Co Ltd, Other Locations 55

Kissei Pharmaceutical Co Ltd, Subsidiaries 55

List of Figures

List of Figures

Kissei Pharmaceutical Co Ltd - Pipeline by Top 10 Indication, 2016 9

Kissei Pharmaceutical Co Ltd - Pipeline by Stage of Development, ...

List of Figures

Kissei Pharmaceutical Co Ltd - Pipeline by Top 10 Indication, 2016 9

Kissei Pharmaceutical Co Ltd - Pipeline by Stage of Development, 2016 11

Kissei Pharmaceutical Co Ltd - Monotherapy Products in Pipeline, 2016 12

Kissei Pharmaceutical Co Ltd - Partnered Products in Pipeline, 2016 13

Kissei Pharmaceutical Co Ltd - Out-Licensed Products in Pipeline, 2016 15

Kissei Pharmaceutical Co Ltd - Pipeline by Top 10 Target, 2016 44

Kissei Pharmaceutical Co Ltd - Pipeline by Route of Administration, 2016 46

Kissei Pharmaceutical Co Ltd - Pipeline by Molecule Type, 2016 47

Kissei Pharmaceutical Co Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016 48

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports